Quantitative analysis identifies opioid and non-invasive therapies in Medicaid populations, suggesting barriers affect treatment access.
Introduction Low back pain is the leading cause of disability worldwide and Medicaid beneficiaries are disproportionally impacted. No studies have comprehensively examined patterns of treatment among Medicaid beneficiaries with low back pain. Methods We quantitatively described modalities of treatment and low value care received following a low back pain diagnosis among Medicaid beneficiaries across the US. We then qualitatively explored factors that influence treatment patterns by interviewing chronic pain experts. Results On average 39.6% of patients received a prescription opioid in the 12 months following diagnosis and 41.2% received conservative therapies—non-invasive, non-pharmacological methods including physical, manual, or psychological therapies. Prescription non-opioid analgesic medications were the most common modality received first (57.8%) and across the 12 months following diagnosis (74.1%). On average 8.9% of patients received high-dose, long-term opioid therapy (>120MME/day for ≥ 90 days) and 31.7% received early imaging; both indicators for low value care. Chronic pain experts highlighted challenges related to Medicaid coverage for conservative therapies, limited access to pain specialists, and social and economic factors influencing treatment access and utilization. Conclusion Barriers including Medicaid coverage limitations, provider access challenges, and economic factors likely impact patterns of low back pain treatment among individuals enrolled in Medicaid.
No takes yet. Share an insight, caveat, or question.
Tormohlen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: